Notícias

Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing.

NASDAQ

Key PointsModerna’s personalized melanoma vaccine, paired with Merck’s Keytruda, cut the risk of recurrence or death by 42% in a Phase 3 trial.

Ler o briefing completo da Veytics

Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.